GLP-1 Drug Usage Patterns Reveal Challenges in Long-Term Adherence
GLP-1 drugs, such as Ozempic and Zepbound, are increasingly used for diabetes and obesity treatment, yet many patients discontinue their use. Dr. Jaime Almandoz from the University of Texas Southwestern Medical Center found that less than 25% of patients remain on these medications after a year. Factors contributing to this include cost, insurance loss, and side effects. Despite this, a significant number of patients express intentions to restart the medication. The pharmaceutical industry is advocating for changes in Medicare rules to increase accessibility, while concerns about muscle loss from intermittent use are being raised by experts. 
